UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorpo ...

® Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update February 24, 2022 The information in this slide deck is current as of February 24, 2022, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, ...

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2021 Results Conference Call February 24, 2022 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations and Corporate Communications Scott Canning - President and Chief Executive Officer James Karrels - Senior Vice President and Chief Financial Office Conference Call Participants Kaveri Pohlman - BTIG Etzer Darout - BMO Capital Markets Asha Babaric - Citi Charles Zhu - Guggenheim Jonathan Miller - Evercore ISI Stephen Willey - Stifel Silvan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR (301) 251-5172 (Registrant's telephone number) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par value $0.01 per share | MGNX | Nasdaq Global Selec ...

® Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update January 10, 2022 The information in this slide deck is current as of January 10, 2022, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, p ...

® Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update November 2, 2021 The information in this slide deck is current as of November 2, 2021, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements 2 Legal Notices Any statements in these materials about future expectations, p ...

MacroGenics, Inc. (NASDAQ:MGNX) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Chris James - Vice President of Investor Relations and Corporate Communications Scott Koenig - President and Chief Executive Officer Jim Karrels - Chief Financial Officer Conference Call Participants Peter Lawson - Barclays Kaveri Pohlman - BTIG Asha Babaric - Citi Jonathan Chang - SVB Leerink Jonathan Miller - Evercore ISI Silvan Tuerkcan - JMP Securities Stephen Willey - Stifel Avatar Jones - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36112 MACROGENICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1591613 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9704 Medical Center Drive ...

MACRO GENICS® Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update September 16, 2021 The information in this slide deck is current as of September 16, 2021, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements September 16, 2021 2 Legal Notices Trademarks DART, TRIDENT, M ...

MacroGenics, Inc. (NASDAQ:MGNX) Q2 2021 Earnings Conference Call July 29, 2021 4:30 PM ET Company Participants Chris James ??? Vice President of Investor Relations and Corporate Communications Scott Koenig ??? President and Chief Executive Officer Jim Karrels ??? Chief Financial Officer Conference Call Participants Carly Kenselaar ??? Citi Jonathan Chang ??? SVB Leerink Jonathan Miller ??? Evercore ISI Stephen Willey ??? Stifel Etzer Darout ??? Guggenheim Securities Cynthia Cintron ??? Cowen Peter Lawson ?? ...